What is Zacks Research’s Forecast for ESPR Q2 Earnings?
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Zacks Research increased their Q2 2026 earnings estimates for shares of Esperion Therapeutics in a note issued to investors on Wednesday, June 4th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of ($0.06) for the quarter, […]
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Zacks Research increased their Q2 2026 earnings estimates for shares of Esperion Therapeutics in a note issued to investors on Wednesday, June 4th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of ($0.06) for the quarter, […]
